<DOC>
	<DOCNO>NCT00020930</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness cetuximab treat patient stage IV colorectal cancer respond previous treatment .</brief_summary>
	<brief_title>Cetuximab Treating Patients With Stage IV Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient irinotecan-refractory , stage IV colorectal cancer treat cetuximab . II . Determine safety toxic effect drug patient . III . Determine time progression patient treat drug . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour weekly 6 week . Treatment repeat absence disease progression unacceptable toxicity . Patients follow 4 week every 3 month thereafter . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 4 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent stage IV colorectal cancer Any T , N , M1 Documented progressive disease within 6 month complete irinotecan contain regimen Bidimensionally measurable metastatic disease Meningeal CNS involvement allow Immunohistochemical evidence EGFR expression ( least 1+ ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 5 time ULN Alkaline phosphatase great 5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No history uncontrolled angina , arrhythmia , congestive heart failure Other : No malignancy within past 3 year except basal cell skin cancer preinvasive carcinoma cervix No uncontrolled seizure disorder No neuropathy great grade 2 neurologic disease No medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine monoclonal antibody therapy cetuximab Chemotherapy : See Disease Characteristics Recovered prior chemotherapy No chemotherapy since complete irinotecancontaining regimen No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 30 day since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 21 day since prior surgery , except diagnostic biopsy , recover Other : At least 30 day since prior investigational agent recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>